ACCENDRA HEALTH INC/VA/ financials

ACH CIK 0000075252

Source: EDGAR filings · Built 2026-06-02T02:13:53Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -292.75M -11.55M 565.81M 164.07M 81.99M 287.92M
EBITDA 241.98M -36.45M 343.60M 371.58M 459.09M 297.45M
Working Capital -399.20M 168.97M 210.91M 728.72M 977.79M 790.14M
Net Debt 1.63B 1.90B 1.96B 2.71B 1.10B 1.11B
Gross Margin 46.68% 82.80% 83.26% 18.35% 15.46% 15.10%
Operating Margin 0.99% -8.12% 5.22% 1.44% 3.77% 2.41%
Net Margin -39.85% -13.53% -1.62% 0.22% 2.26% 0.35%
Return on Equity (ROE) 238.76% -61.85% -4.37% 2.32% 23.61% 4.20%
Return on Assets (ROA) -44.89% -7.79% -0.81% 0.42% 6.27% 0.90%
Current Ratio 0.58× 1.09× 1.11× 1.47× 1.73× 1.59×
Debt-to-Equity -4.15× 3.29× 2.33× 2.87× 1.23× 1.67×
Effective Tax Rate -0.71% -6.32% 41.66% -105.57% 19.93% 19.87%
Cash Conversion Ratio 0.09× -0.45× -17.93× 14.52× 0.56× 11.36×
Accruals Ratio -0.41× -0.11× -0.15× -0.06× 0.03× -0.09×
SBC % of Revenue 0.47% 0.62% 0.56% 0.21% 0.26% 0.24%
CapEx Coverage -0.53× 0.93× 4.24× 2.02× 2.94× 6.61×
Free Cash Flow Per Share $-3.81 $-0.15 $7.31 $2.15 $1.09 $4.53

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 67.34× 14.80× 57.55×
P/FCF 2.63× 9.07× 40.05× 5.97×
FCF Yield 37.95% 11.02% 2.50% 16.76%
EV / EBITDA 7.63× 9.98× 11.29× 9.53× 10.40×
P/S 0.08× 0.38× 0.58× 0.15× 0.34× 0.23×
P/B 1.72× 1.56× 1.54× 3.50× 2.79×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 2.76B 2.68B 2.55B 9.96B 9.79B 8.48B
Cost of Revenue 1.47B 1.40B 1.34B 8.13B 8.27B 7.20B
Gross Profit 2.22B 2.13B 1.83B 1.51B 1.28B
Research and Development Expense 13.00M 13.00M 12.00M 12.10M
Selling, General and Administrative Expense 1.07B 1.08B 1.00B 1.55B 1.08B 1.04B
Operating Income (Loss) 27.46M -217.73M 133.23M 142.91M 368.47M 204.12M
Income Tax Expense (Benefit) 729.00K 20.85M 6.36M -11.50M 55.16M 21.83M
Net Income (Loss) Attributable to Parent -1.10B -362.69M -41.30M 22.39M 221.59M 29.87M
Earnings Per Share, Basic $-14.31 $-4.73 $-0.54 $0.30 $3.05 $0.47
Weighted Average Number of Shares Outstanding, Basic 76.90M 76.74M 75.78M 74.50M 72.74M 63.37M
Earnings Per Share, Diluted $-14.31 $-4.73 $-0.53 $0.29 $2.94 $0.47
Weighted Average Number of Shares Outstanding, Diluted 76.90M 76.74M 77.37M 76.22M 75.49M 63.51M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 281.99M 27.57M 243.04M 69.47M 55.71M 83.06M
Assets, Current 547.87M 2.02B 2.10B 2.30B 2.32B 2.14B
Assets 2.45B 4.66B 5.09B 5.39B 3.54B 3.34B
Long-term Debt 1.03B
Liabilities, Current 947.08M 1.85B 1.89B 1.57B 1.34B 1.35B
Long-term Debt, Excluding Current Maturities 986.02M
Liabilities 2.91B 4.07B 4.17B 4.44B 2.60B 2.62B
Stockholders' Equity Attributable to Parent -460.98M 586.36M 945.30M 966.74M 938.50M 712.05M
Common Stock, Shares, Outstanding 76.39M 77.20M 76.55M 76.28M 75.43M 73.47M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 161.50M 740.71M 325.01M 124.18M 339.22M
Payments to Acquire Property, Plant, and Equipment 190.96M 170.29M 172.38M 158.09M 40.98M 50.42M
Net Cash Provided by (Used in) Investing Activities 144.42M -116.53M -137.25M -1.80B -53.63M 80.07M
Payments for Repurchase of Common Stock 10.18M
Payments of Dividends 0 0 731.00K 648.00K
Net Cash Provided by (Used in) Financing Activities 188.08M -267.60M -417.33M 1.50B -129.48M -379.39M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ACH CIK 0000075252), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

MRX

Marex Group plc

USAR

USA Rare Earth, Inc.

DBRG

DigitalBridge Group, Inc.